U.S. FDA authorizes Merck’s at-home antiviral COVID-19 pill

FILE PHOTO: An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS

December 23, 2021 (Reuters) – The U.S. on Thursday authorized Merck & Co’s (MRK.N) antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving the go-ahead to a similar but more effective treatment from Pfizer Inc (PFE.N).

Merck’s drug, Molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.

The U.S. Food and Drug Administration authorized Merck’s drug to treat mild-to-moderate COVID-19 in adults who are at risk for severe disease, and for whom alternative COVID-19 treatments are not accessible or clinically appropriate.

Pfizer’s drug, Paxlovid, was authorized on Wednesday for people aged 12 and older and has shown to be nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to trial data. 

The Pfizer treatment’s two-drug regimen may not be appropriate for some patients because it includes an older antiviral called ritonavir that is known to have interactions with some other prescription medicines.

The agency’s decision on Thursday comes despite concerns about its use by some outside advisers to the FDA.

Both the Merck and Pfizer pills could be promising tools for those who are sick with COVID-19, especially in the face of the fast-spreading Omicron variant, which is now dominant in the United States. Some existing monoclonal antibody therapies given in the hospital are not as effective against Omicron.

“This drug is also incredibly easy to use,” Nick Kartsonis, senior vice president of clinical research for vaccines and infectious diseases told Reuters.

“It doesn’t require any second drug to boost its efficacy, and you can give it in a variety of special patient populations, including people who have significant issues with liver function or kidney function, and you don’t have to worry about concomitant medications.”

Merck’s drug is not authorized for use in patients younger than 18 because Molnupiravir may affect bone and cartilage growth, the FDA said. The pill is not recommended for use during pregnancy, the agency added.

The drug is meant to be taken twice a day – four pills each time – for five days, making a full treatment course of 40 pills.

The U.S. government’s contract for 10 million courses of the Pfizer drug at a price of $530 per course compares to the deal with Merck for as many as 5 million courses of Molnupiravir at a price of $700 per course.

Paul Schaper, Merck’s head of global public policy, said the company will ship hundreds of thousands of treatment within several days and million courses of treatment within several weeks in the United States.

“We have entered into agreements with the US government for slightly more than 3 million doses, 3 million courses of treatment over 2021 and 2022,” Schaper told Reuters.

Merck has said Molnupiravir, which helps prevent the virus from replicating, should be effective against any variant, including the new Omicron variant.

Source: Reuters



Comments

comments